We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Neutralisierende Antikörper gegen Interferon-beta in der Therapie der Multiplen Sklerose.
- Authors
Gneiss, Claudia; Deisenhammer, F.
- Abstract
Interferon-beta (IFN-ß) is established as first-line therapy in patients with relapsing multiple sclerosis. Three different IFN-ß preparations, two IFN-ß-la (Avonex® and Rebif®) products and one IFN-ß-lb (Betaferon®) product, have been licensed for this indication. One disadvantage related to this treatment is the potential occurrence of neutralizing antibodies (NABs) against IFN-ß in up to one-third of patients. NABs reduce the biological activity of IFN-ß by blocking the receptor binding of IFN-ß. Several studies have demonstrated that NABs also reduce clinical efficacy. While most patients develop NABs between 6 and 18 months of therapy, the negative influence on the clinical effects is delayed and does not occur before the second or third year of IFN-ß therapy. NAB-positive patients show the tendency to revert to NAB-negative status even though treatment is continued, and therefore NABs underlie a dynamic process. There is evidence that the reversion to NAB-negative status may be accelerated by different factors. We advocate an early and continuous NAB screening to identify NAB-positive patients in order to plan clinical studies and develop effective strategies for these patients. Currently, NAB detection methods are too diverse and therefore need to be standardized.
- Publication
Journal of Laboratory Medicine / Laboratoriums Medizin, 2003, Vol 27, Issue 9/10, p339
- ISSN
0342-3026
- Publication type
Article